As a Fulbright-Fogarty fellow, Katie Farkouh will spend nine months in Accra, Ghana, studying urinary tract infection (UTI) risk and treatment outcomes in children with sickle cell disease.
How a person’s immune system responds to a protein called LL-37 may increase risk for developing acute coronary syndrome, but the response may also serve as a potential target for future treatments.
In a new multicenter international study led by the Mayo Clinic Comprehensive Cancer Center, researchers found that people with the B-cell precursor subtype of acute lymphoblastic leukemia (BCP-ALL), who also lacked a genetic abnormality known as the Philadelphia chromosome and were in remission with no trace of cancer, showed significantly higher survival rates when blinatumomab was added to their chemotherapy treatment.
bioMérieux, a world leader in in vitro diagnostics, today announces that its VITEK® REVEAL™ AST System, reporting results directly from positive blood cultures, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.
A new study has discovered genetic markers in inflammation that may be related to a second stroke or other major cardiovascular event following a stroke. These findings could help identify drug targets to mitigate stroke-related disability and mortality.
Relapsed B-cell ALL is the leading cause of cancer-related deaths in children and young adults. UniSA research has shown the potential of new microfluidic technology, to improve the CAR T-cell manufacturing process by efficiently removing contaminating cancerous cells and other large white blood cells - potentially leading to greater access and lower costs of treatment.
In 2022, Alaggio and colleagues revised the WHO Classification of Haematolymphoid Tumors resulting in elimination of the provisional diagnostic categories of Hairy Cell Leukemia Variant (HCLv) and B Prolymphocytic Leukemia.
A new study in mice hints at the promise of an eventual alternative treatment option for the “wet” version of age-related macular degeneration (AMD).
Vanderbilt University Medical Center (VUMC) researchers are touting data from a multicenter, international phase 2 clinical trial showing a new, curative treatment for sickle cell disease (SCD).
Dr. Zhen Mei, a clinical pathologist, and Dr. Vivian Chang, a pediatric hematologist-oncologist, both at UCLA Health, have been awarded $30,000 from the American Society of Hematology to revise blood cell ranges for people with Duffy-null Associated Neutrophil Count, which is also known as Duffy-negative
In Greek mythology, a Chimera is a creature of change, a being possessing the forms of lion, goat and dragon. But unlike the mythical creature, a new approach to fighting cancer cells throughout the body is very real and has arrived at The University of New Mexico Comprehensive Cancer Center.
Curious by Nature, presented by Newswise, is a podcast for curious people. In each episode, listeners can travel briefly into the fascinating world that comes with years of dedication to one field of study. Be inspired by the many amazing things that are going on right now, some of which may have a major effect on our lives. Enjoy this concentrated knowledge from experts.
The International Society on Thrombosis and Haemostasis (ISTH), the leading international professional medical-scientific organization dedicated to advancing the understanding, prevention, diagnosis, and treatment of conditions related to thrombosis and hemostasis, has published the first clinical practice guideline utilizing strict GRADE methodology for the treatment of congenital hemophilia A and B.
Indiana University School of Medicine researchers and their collaborators have uncovered molecular insights expected to enhance treatment options for acute myeloid leukemia (AML), a rare and severe blood and bone marrow cancer.
Heart attacks have been the leading cause of death in the U.S. for a century. While most treatments for cardiac events target breaking down blood clots, Georgia Tech researchers have found a way to prevent blood clots from even forming. Dramatically, their drug is shown to completely knock out the formation of blood clots without increasing the risks of bleeds in vivo.
Researchers have presented the latest findings from a clinical trial aimed at discovering a cure for sickle cell disease, a painful genetic blood disorder with limited treatment options.
Developmental biologist and stem cell investigator David Traver, PhD, has been named director of a new developmental biology and regenerative pediatrics center at Cedars-Sinai Guerin Children’s.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research, and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
